TY - JOUR
T1 - Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
AU - Kasamon, Yvette L.
AU - Jacene, Heather A.
AU - Gocke, Christopher D.
AU - Swinnen, Lode J.
AU - Gladstone, Douglas E.
AU - Perkins, Brandy
AU - Link, Brian K.
AU - Popplewell, Leslie L.
AU - Habermann, Thomas M.
AU - Herman, Joseph M.
AU - Matsui, William H.
AU - Jones, Richard J.
AU - Ambinder, Richard F.
PY - 2012/5/3
Y1 - 2012/5/3
N2 - In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab- ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69% had stage IIB-IV disease; 8% had CD20- Hodgkin and Reed- Sternberg cells. Rituximab-ABVD was generally well tolerated. Delivered relative dose intensity was 94% forAVD and 79% for bleomycin. After 6 cycles, 81% of patients were in complete remission. Only 8% received radiation therapy. The actuarial 3-year event-free and overall survival rates were 83% and 98%, respectively. EBV copy number in plasma fell dramatically during cycle 1 in patients with EBV- tumors. Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as NCT00369681.
AB - In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab- ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69% had stage IIB-IV disease; 8% had CD20- Hodgkin and Reed- Sternberg cells. Rituximab-ABVD was generally well tolerated. Delivered relative dose intensity was 94% forAVD and 79% for bleomycin. After 6 cycles, 81% of patients were in complete remission. Only 8% received radiation therapy. The actuarial 3-year event-free and overall survival rates were 83% and 98%, respectively. EBV copy number in plasma fell dramatically during cycle 1 in patients with EBV- tumors. Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as NCT00369681.
UR - http://www.scopus.com/inward/record.url?scp=84860741107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860741107&partnerID=8YFLogxK
U2 - 10.1182/blood-2012-01-402792
DO - 10.1182/blood-2012-01-402792
M3 - Article
C2 - 22343727
AN - SCOPUS:84860741107
SN - 0006-4971
VL - 119
SP - 4129
EP - 4132
JO - Blood
JF - Blood
IS - 18
ER -